Recombinant Human Transmembrane protein 192 (TMEM192)

What is the basic structure of human TMEM192?

TMEM192 is a 271-residue lysosomal/late endosomal protein with four transmembrane segments. Both N- and C-termini face the cytosol, as confirmed by immunogold labeling and proteinase protection assays . The protein forms homodimers linked by disulfide bridges, specifically through Cys266 in the C-terminal region . This is particularly interesting as this cysteine would be predicted to localize in the reductive environment of the cytosol, where disulfide bridges are generally uncommon .

How is TMEM192 targeted to lysosomes?

Lysosomal targeting of TMEM192 is mediated by two directly adjacent N-terminally located dileucine motifs of the DXXLL-type . Experimental evidence using CD4 chimeric constructs and targeted mutagenesis has shown that disruption of both dileucine motifs results in mistargeting of TMEM192 to the plasma membrane, while each individual motif is sufficient to ensure correct targeting to late endosomes/lysosomes .

What is the expression pattern of TMEM192 across tissues?

TMEM192 exhibits ubiquitous tissue expression with varying levels:

Source: Based on Western blot analysis of murine tissues .

What antibodies are available for studying TMEM192?

Multiple antibodies have been developed for TMEM192 research, including:

• Rabbit monoclonal antibodies TMEM192AB1 (recognizing C-terminal residues 235-250) and TMEM192AB2 (recognizing residues 200-235)

• Rabbit polyclonal antibodies suitable for immunoprecipitation (IP), Western blotting (WB), immunohistochemistry (IHC-P), and immunofluorescence (ICC/IF)

• Species-specific antibodies with varying epitopes (e.g., antibodies against N-terminal epitopes of murine TMEM192)

When selecting antibodies, researchers should consider both the species of interest and the specific epitope, especially when working with truncated forms or processed fragments of TMEM192.

How can lysosomal isolation techniques utilizing TMEM192 be implemented?

Two primary methodologies have been developed:

• LysoTag Method:

  • Requires exogenous expression of TMEM192 with epitope tags (typically three tandem HA epitopes at C-terminus)

  • Applicable to cell culture models and genetically modified mice

  • Allows rapid immunoprecipitation of lysosomes using anti-HA antibodies

• Tagless LysoIP Method:

  • Utilizes antibodies against endogenous TMEM192

  • Applicable to clinical samples and human-derived cells without genetic modification

  • Protocol involves:
    a) Homogenization in isotonic buffer using a ball bearing homogenizer
    b) Incubation with anti-TMEM192 antibodies coupled to magnetic beads
    c) Isolation of intact lysosomes suitable for multiple downstream analyses

This approach enables multimodal omics analyses of lysosomal content from clinical samples, particularly valuable for lysosomal storage disease research.

What role does TMEM192 play in autophagy regulation?

Research findings on TMEM192's role in autophagy reveal context-dependent effects:

• In tumor cells (HepG2 hepatoma):

  • TMEM192 knockdown activates autophagy, as evidenced by increased LC3-II expression

  • This is linked to growth inhibition and increased apoptosis via the mitochondrial pathway

  • Blocking the expression of key autophagy gene Atg7 inhibits the increased apoptosis in TMEM192-deficient cells

• In TMEM192-/- MEFs:

  • Normal LC3-II/I ratios and no accumulation of p62 under basal conditions

  • Comparable autophagic flux during starvation or Bafilomycin treatment to wild-type cells

  • Unaffected fusion of autophagosomes and lysosomes

  • Normal mTORC1 activity regulation (monitored through S6K phosphorylation)

These contrasting observations suggest cell type-specific or context-dependent functions of TMEM192 in autophagy regulation.

How does TMEM192 deficiency affect tumor cell growth?

TMEM192 appears to be important for tumor cell growth and proliferation. Studies have shown:

• TMEM192 is highly expressed in tumor cell lines compared to normal cell lines

• Knockdown of TMEM192 using siRNAs in HepG2 hepatoma cells results in:

  • Growth inhibition

  • Increased apoptosis

  • Activation of autophagy (detected through LC3-II expression)

The mechanism involves a crosstalk between autophagy and apoptosis, where TMEM192 deficiency triggers autophagy, which subsequently activates apoptosis through the mitochondrial pathway . This suggests that targeting TMEM192 could potentially be explored as a therapeutic approach for certain cancers.

How can TMEM192 be used in lysosomal storage disorder research?

The tagless LysoIP method utilizing TMEM192 has been validated for lysosomal disease research:

• Successfully applied to isolate lysosomes from peripheral blood mononuclear cells (PBMCs) of CLN3 disease patients

• Metabolic profiling of isolated lysosomes revealed massive accumulation of glycerophosphodiesters (GPDs) in patients' lysosomes

• The method allows for biomarker discovery and disease monitoring in human lysosomal storage disorders

This approach overcomes previous limitations in studying lysosomal content directly from patient samples, enabling both biomarker discovery and deeper understanding of disease pathology.

What are the apparent contradictions in TMEM192 research that require further investigation?

Several notable contradictions in current research findings warrant further investigation:

These contradictions suggest potential compensatory mechanisms in vivo, cell type-specific functions, or context-dependent roles that require further elucidation through targeted experimental approaches.

What methodological considerations are important when studying TMEM192 proteolytic processing?

TMEM192 processing occurs after lysosomal targeting by pH-dependent lysosomal proteases. When investigating this process:

• Disruption of lysosomal acidification (using Bafilomycin A1 or NH4Cl) prevents generation of the N-terminal fragment

• Standard protease inhibitors targeting serine, cysteine, aspartyl, and metalloproteases do not completely prevent fragment generation

• Processed fragments should be analyzed under non-reducing and reducing conditions to assess disulfide linkage status

• Tissue-specific differences in processing efficiency should be considered when comparing results across different experimental systems

What are promising avenues for future TMEM192 research?

Based on current knowledge gaps, these research directions appear most promising:

• Molecular Function Determination:

  • Identification of TMEM192 binding partners through proximity labeling approaches

  • Investigation of potential ion or metabolite transport functions

  • Structural studies to understand the dimerization interface and functional domains

• Cancer Biology Applications:

  • Exploration of TMEM192 as a therapeutic target in cancer

  • Investigation of its differential expression across cancer types

  • Determination of mechanisms underlying its role in tumor cell survival

• Lysosomal Biology:

  • Further development of TMEM192-based methods for studying lysosomal content in health and disease

  • Investigation of its potential role in lysosomal nutrient sensing or membrane dynamics

  • Elucidation of compensatory mechanisms in TMEM192-deficient systems

What technical challenges should researchers anticipate when working with TMEM192?

Researchers should be prepared to address several technical challenges:

• Species-specific antibody recognition, requiring careful validation when switching between model systems

• Potential artifacts from overexpression systems, necessitating comparison with endogenous protein behavior

• Tissue-specific processing patterns that may complicate interpretation of experimental results

• Context-dependent functional effects that vary between cell types and physiological conditions

• Need for appropriate controls when using TMEM192 for lysosomal isolation to avoid isolation artifacts